Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02260258 · ClinicalTrials.gov registry record · Phase 2
Neuromuscular Blockade for Post-Cardiac Arrest Care
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT02260258 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 83 participants.
The verdict
NCT02260258, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate if neuromuscular blockade improves lactate clearance (and preliminary secondary clinical outcome measures) as compared to usual care in post-cardiac arrest patients undergoing targeted temperature management.
Interventions
- DRUG Rocuronium
- DRUG Normal Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-05-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02260258
The ClinicalTrials.gov registry entry for NCT02260258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rocuronium is the first listed.
NCT02260258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02260258 about?
NCT02260258 is a clinical study titled "Neuromuscular Blockade for Post-Cardiac Arrest Care". The main purpose of this study is to evaluate if neuromuscular blockade improves lactate clearance (and preliminary secondary clinical outcome measures) as compared to usual care in post-cardiac arrest patients undergoing targeted temperature management.
What is the current status of trial NCT02260258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2014-10. Estimated completion is 2019-05-29.
What interventions are being tested in trial NCT02260258?
The interventions under investigation include: Rocuronium (DRUG), Normal Saline (DRUG).
Who is sponsoring clinical trial NCT02260258?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.